EyePoint Pharmaceuticals has licensed its Dexycu anti-inflammation drug to Chinese pharmaceutical company Ocumension Therapeutics for distribution in Hong Kong, Macau and mainland China.
Through the licensing agreement, EyePoint will receive $2 million up front as well as royalties on Dexycu sales by Ocumension. EyePoint is also eligible for an additional $12 million if commercial and regulatory milestones are made by Ocumension, which will have exclusive rights to commercialize and develop the product in agreed-upon territories.
“Dexycu is an important addition to our growing portfolio of ocular disease treatments for patients in the greater China region and continues our strong partnership with EyePoint,” said Ye Liu, CEO of Ocumension. “There is a need for innovation to replace the burdensome steroid eyedrop regimen prescribed for post-cataract surgery inflammation which has low patient compliance due to its complex dosing schedule."
Dexycu is currently marketed by EyePoint in the U.S., and is used to treat inflammation after ocular surgery.